The Broad Institute, Boston Children’s Hospital, and The Jackson Laboratory launched a new Center for Therapeutic Genetics to build gene therapies for people with rare diseases and standardize methods for wider clinical adoption. The program is designed to treat gene editing as a hospital-like clinical procedure, with the aim of reducing the need for bespoke regulatory pathways for every individual use. The center targets development of a gene-editing platform for rare pediatric epilepsies, including alternating hemiplegia of childhood (ATP1A3 mutation) and Dravet syndrome (SCN1A mutations), supported by a $34.5 million ARPA-H grant awarded earlier in the month. The partners said they aim to treat a first patient within three years. Beyond the initial epilepsies, the center plans to expand into liver diseases and additional indications. Winston Yan, named founding director of the nonprofit effort, said the center would emphasize selecting patient and program targets to establish a cadence of successes. Regulatory and operational complexity has been a major bottleneck in gene therapy scaling; the center’s approach is a direct attempt to marry therapeutic genetics workflows with healthcare delivery models.